Pan‐cancer analysis of <scp>TIM</scp>‐3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity

Abstract

These observations indicate that TIM-3 RNA expression is heterogeneous, but more common in pancreatic cancer and in tumors exploiting PD-L1 and CTLA-4 checkpoints. Clinical trials with patient selection for matched immune-targeted combinations may be warranted.